Health Condition 1: null- Patients having Chronic plaque psoriasis vulgaris Health Condition 2: L400- Psoriasis vulgaris
Conditions
Interventions
Intervention1: Isotretinoin: Group A: Patients on oral PUVA Sol alone
â?¢ In oral PUVA Sol, 8-MethoxyPsoralen (8-MOP) is administered orally in Morning with Breakfast followed by Sunlight exposure aft
Sponsors
Sri Ram Murti Smarak Institute of Medical Sciences Bareilly
Eligibility
Inclusion criteria
Inclusion criteria: • Clinically diagnosed case of Psoriasis vulgaris with BSA > 10 % • Age more than or equal to 18 years • Patients should be willing for Investigation, Treatment and Regular Follow up
Exclusion criteria
Exclusion criteria: • Age less than 18 years or more than 60 years • Pregnancy or Lactation at present • Hepatic, Renal, Lipid Profile Abnormalities • Photo aggravated Psoriasis/ Photodermatoses • Past/Present history of any type of Malignancy • Patient unsure about attending treatment Schedule Regularly • Previous H/o any Hypersensitivity Reaction to Systemic Retinoids and/or Psoralens • Patients who fail to come for follow up after Initiation of therapy • Patients with previous H/o Immunobullous disorders • Patients on phototoxic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| â?¢ Time taken to reach PASI 50 (it means 50% reduction in original PASI) â?¢ Cumulative dose of Isotretinoin â?¢ Number of exposures/time interval of PUVA SolTimepoint: 4, 8 and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in Dermatology Quality of Life IndexTimepoint: 4, 8 and 12 weeks;Safety profile of isotretinoin when given for psoriasis in the dosage of 0.5 mg/kg dailyTimepoint: 4, 8 and 12 weeks;Time taken for the recurrence of psoriasisTimepoint: 4,8 and 12 weeks | — |
Countries
India
Contacts
Public ContactDr H S Soodan
Sri Ram Murti Smarak Institute of Medical Sciences, Bareilly (UP)
Outcome results
None listed